Actively Recruiting
Evaluating Safety and Effectiveness of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder
Led by Newleos Therapeutics, Inc. · Updated on 2026-07-09
100
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of a new drug called NTX-1472, a V1a receptor antagonist, in adults with Social Anxiety Disorder SAD. This Phase 2 clinical trial aims to determine how safe and well tolerated NTX-1472 is, and how effectively it treats adults living with SAD. The study compares NTX-1472 to a matching placebo to better understand its impact on this condition. Participants will take either NTX-1472 or a placebo capsule once daily for 8 weeks. The study involves two groups one receiving the experimental drug and the other receiving the placebo. Over 14 weeks, participants will visit the clinic six times for health checkups and various tests related to the treatment and their condition. During the study, participants will undergo multiple assessments including the Liebowitz Social Anxiety Scale LSAS, Hamilton Anxiety Rating Scale HAM-A, and other scales measuring anxiety, depression, stress, loneliness, sleep quality, and overall severity of symptoms. Researchers will monitor any treatment-emergent adverse events from the start until week 8. This detailed evaluation helps assess the drugs safety and effects while participants continue their involvement over the full 14-week period.
CONDITIONS
Brief Title
A Study of NTX-1472 in Social Anxiety Disorder
Research Team
N
Newleos Therapeutics Clinical Trial Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
